Application of Translational Science to Clinical Development - Genomic Biomarkers for Pharmaceutical Development - page 18

In summary, we have described broad strategies to identify the right drug at the right
dose for the right patient. By capitalizing on technological improvements in genomics, we
believe that the future of drug development is bright so long as we put the patient first, i.e.,
understand the molecular heterogeneity within a disease and then develop therapeutics that
are targeted to particular subsets of patients. This translational approach, in turn, is likely to
increase the probability of success of clinical trials, a pre-requisite for a sustainable pharma
business.
References
[1] Thomas K. Generic drug makers see a drought ahead. New York Times 2012;December 4:B1.
[2] Allison M. Reinventing clinical trials. Nat Bio 2012;30:41-9.
[3] Arrowsmith J. A decade of change. Nat Rev Drug Discov 2012;11:17-18.
[4] Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat
Med 2011;17:297-303.
[5] Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anti-cancer drug development.
Nat Rev Cancer 2010;7:514-23.
[6] Xalkori Package Insert. < Xalkori.com >, accessed February 2013.
[7] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identiication of the transforming
EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007;448:561-6.
[8] Ou S-HI. Crizotinib: a novel and irst-in-class multitargeted tyrosine kinase inhibitor for the treatment of
anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des, Dev Ther
2011;5:471-85.
[9] Chvetzoff G, Tannock IF. Placebo effects in oncology. J Natl Cancer Inst 2003;95:19-29.
[10] Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;14:5984-93.
[11] Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of
response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
[12] Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and ben-
eit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
[13] Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for
panitumumab eficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
[14] Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn Jr WD, Morse D, et al. United States Food and Drug
Administration Drug Approval summary: Geitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-18.
[15] Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, et al. Approval summary for erlotinib for
treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one
prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-21.
[16] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations
in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geitinib.
N Engl J Med 2004;350:2129-39.
[17] Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation
with clinical response to geitinib therapy. Science 2004;304:1497-500.
[18] Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common
in lung cancers from 'never smokers' and are associated with sensitivity of tumors to geitinib and erlotinib.
Proc Natl Acad Sci U S A 2004;101:13306-11.
[19] Kris MG, Herbst R, Rischin D, LoRusso P, Baselga J, Hammond L, et al. Objective regressions in non-small
cell lung cancer patients treated in Phase I trials of ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that
blocks the epidermal growth factor receptor (EGFR). Lung Cancer 2000;2972(Suppl. 1) poster 233.
[20] Kris MG, Natale RB, Herbst RS, et al. Eficacy of geitinib, an inhibitor of the epidermal growth factor recep-
tor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. a randomized trial. JAMA
2003;290:2149-58.
[21] Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized Phase II trial of geitinib for previously
treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.